The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Is mini-hyper-CVD plus venetoclax safe and effective in patients with R/R Ph- ALL?
During the 2023 European Hematology Association (EHA) Congress, the ALL Hub spoke to Fadi Haddad, MD Anderson Cancer Center, US. We asked, is mini-hyper-CVD plus venetoclax safe and effective in patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL)?
Is mini-hyper-CVD plus venetoclax safe and effective in patients with R/R Ph- ALL?
Haddad provided the rationale for this study by highlighting the synergistic effects and promising activity of the BCL2 inhibitor venetoclax plus chemotherapy in pre-clinical studies, as well as in patients with R/R ALL. This phase II trial included patients with R/R B-cell or T-cell ALL who received a median of two prior lines of therapy and had poor risk cytogenetics. Study endpoints included the safety profile, response rates, and survival outcomes.
Haddad concluded that mini-hyper-CVD plus venetoclax proved clinically effective and safe in patients with R/R Ph-ALL and, while it is not a definitive combination therapy, it could serve as a potential bridging therapy to stem cell transplantation or other therapies.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?